LYCOS RETRIEVER 
King Pharmaceuticals: Results
built 629 days ago
BRISTOL , Tenn. , Sept. 6 /PRNewswire-FirstCall/ -- King Pharmaceuticals, Inc. (NYSE: KG) today reported the publication of the results of the Heart Outcomes Prevention Evaluation - The Ongoing Outcomes ("HOPE-TOO"). The HOPE- TOO results are published in an article entitled "Long-Term Effects of Ramipril on Cardiovascular Events and on Diabetes" which appears in the August 30, 2005 issue of Circulation, a publication of the American Heart Association.
Source:
BRISTOL, Tenn.-- (BUSINESS WIRE) -- King Pharmaceuticals, Inc. (NYSE:KG) announced today that total revenues increased 11% to $545 million during the third quarter ended September 30, 2007, compared to $492 million in the third quarter of 2006. As a result of the special charges detailed below, the reported net loss equaled $41 million and diluted loss per share equaled $0.17 during the third quarter of 2007, compared to net earnings of $90 million and diluted earnings per share of $0.37 in the third quarter of the prior year. Excluding special items, net earnings equaled $128 million and diluted earnings per share equaled $0.52 during the third quarter ended September 30, 2007, compared to net earnings of $106 million and diluted earnings per share of $0.44 in the third quarter of 2006.
Source:
ATLANTA, GA -- (MARKET WIRE) -- October 19, 2005 -- Harte-Hanks (NYSE: HHS) today announced that its client, King Pharmaceuticals, is a Direct Marketing Association 2005 International ECHO Bronze Award recipient in the "Pharmaceutical/Healthcare" category. The DMA International ECHO Awards honor direct and interactive marketing campaigns that demonstrate innovative strategy, database techniques, creativity and, importantly, results. King Pharmaceuticals was selected for its physician-focused, integrated direct marketing campaign driving the Intal® Inhaler brand for the treatment of mild to moderate persistent asthma, and helping to revive the 17-year-old brand without the use of a field sales force.
Source:
MORE ABOUT
Results